Selank: Complete Research Guide

Selank is a synthetic heptapeptide developed at the Institute of Molecular Genetics of the Russian Academy of Sciences. It is a modified analogue of tuftsin, a naturally occurring tetrapeptide (Thr-Lys-Pro-Arg) that is a fragment of the Fc region of immunoglobulin G (IgG). By adding a Pro-Gly-Pro sequence to tuftsin, the researchers created a compound with both the immune-modulating properties of tuftsin and novel anxiolytic (anti-anxiety) and nootropic (cognitive-enhancing) effects.

Selank was approved in Russia in 2009 as a nasal spray medication for the treatment of generalised anxiety disorder (GAD) and as a nootropic for cognitive enhancement. This makes it one of the few peptides in our library with regulatory approval (albeit only in Russia). It is marketed under the trade name Selank®.

What makes Selank particularly interesting from a research perspective is its dual mechanism: it functions simultaneously as an anxiolytic (reducing anxiety without sedation) and as an immunomodulator (enhancing immune function). This combination is unusual in pharmacology, where most anxiolytic drugs (like benzodiazepines) tend to suppress immune function. Selank has been studied for anxiety disorders, cognitive impairment, immune deficiency, and neurasthenic conditions.

Selank is a synthetic heptapeptide with the sequence Thr-Lys-Pro-Arg-Pro-Gly-Pro and a molecular weight of approximately 751 Da. It was designed by extending the naturally occurring tetrapeptide tuftsin (Thr-Lys-Pro-Arg) with a glyproline sequence (Pro-Gly-Pro).

Tuftsin itself is a physiologically active peptide produced by enzymatic cleavage of the heavy chain of IgG in the spleen. It is a natural immune modulator that enhances the phagocytic activity of macrophages and neutrophils. However, tuftsin has a very short half-life in vivo, limiting its therapeutic utility.

The addition of the Pro-Gly-Pro sequence to create Selank served multiple purposes: • Significantly increased metabolic stability and half-life • Conferred novel anxiolytic and nootropic properties not present in tuftsin alone • Maintained and potentially enhanced the immunomodulatory properties of the parent molecule

Selank is primarily administered intranasally (as a nasal spray), which allows it to bypass the blood-brain barrier to some extent via the olfactory and trigeminal nerve pathways. This route is relevant because many of Selank's effects are mediated through the central nervous system. It can also be administered subcutaneously.

The approved Russian pharmaceutical product (Selank® nasal spray) contains a 0.15% solution of Selank. In research settings, it is also available as a lyophilised powder.

Selank's mechanism of action involves multiple neurotransmitter systems and immune pathways.

GABAergic System Modulation: Selank enhances the activity of the GABA (gamma-aminobutyric acid) system, the brain's primary inhibitory neurotransmitter system. Unlike benzodiazepines, which directly bind to GABA-A receptors, Selank appears to modulate GABAergic transmission indirectly, possibly by affecting GABA synthesis, release, or receptor sensitivity. This produces anxiolytic effects without the sedation, cognitive impairment, or addiction risk associated with benzodiazepines.

Serotonergic System: Research indicates Selank modulates serotonin (5-HT) metabolism. It has been shown to influence the expression of genes involved in serotonin synthesis and metabolism, including tryptophan hydroxylase (the rate-limiting enzyme in serotonin production). This may contribute to its mood-stabilising and anxiolytic effects.

BDNF (Brain-Derived Neurotrophic Factor): Selank has been shown to increase the expression of BDNF, a key neurotrophin involved in neuronal survival, growth, and synaptic plasticity. BDNF is critical for learning and memory, and its deficiency is implicated in depression and cognitive decline. This mechanism likely underlies Selank's nootropic effects.

Enkephalin System: Research suggests Selank inhibits the enzymes that degrade enkephalins (endogenous opioid peptides), effectively increasing their concentration and activity. This may contribute to both its anxiolytic and analgesic properties.

Immune Modulation: Retaining tuftsin's immunomodulatory properties, Selank enhances the phagocytic activity of macrophages and neutrophils, stimulates IL-6 production, and modulates the balance of T-helper cell subsets. It has been shown to increase the expression of several immune-related genes.

Gene Expression: Microarray studies have shown that Selank influences the expression of 84 genes involved in various biological processes, including inflammation, immune response, and neuroprotection.

Selank has been studied in both clinical and preclinical settings, with its approved indication in Russia providing the strongest clinical evidence base.

• Generalised Anxiety Disorder (GAD): Selank's approved indication in Russia. Clinical trials demonstrated efficacy comparable to benzodiazepines in reducing anxiety scores on standardised scales (Hamilton Anxiety Rating Scale), without the sedation, cognitive impairment, or dependence risk. The effect builds over 2–4 weeks of use.

• Cognitive Enhancement: Research has shown Selank improves attention, memory formation, and learning in both healthy subjects and those with cognitive impairment. These effects are attributed to its influence on BDNF expression and serotonergic modulation.

• Neurasthenia: Clinical studies in Russia have shown efficacy in treating neurasthenic conditions (chronic fatigue, irritability, concentration difficulties).

• Immune Modulation: Selank has demonstrated the ability to enhance immune function in immunocompromised individuals. It has been studied in the context of upper respiratory infections, showing reduced incidence and duration of illness.

• Depression: Preliminary research suggests anxiolytic and mood-stabilising effects that may be relevant to depression, though this is not an approved indication.

• PTSD and Stress-Related Disorders: Early research has explored Selank's potential in post-traumatic stress disorder and chronic stress conditions, leveraging its dual anxiolytic and immune-supporting properties.

• Neuroprotection: Preclinical studies have investigated Selank's potential to protect neurons from oxidative stress and excitotoxicity, relevant to neurodegenerative conditions.

Dosage information for Selank comes from both the approved Russian pharmaceutical product and research literature.

Approved Dosage (Selank® Nasal Spray, Russia): • 250–300 mcg per administration (3 drops of 0.15% solution per nostril) • 3 times daily • Total daily dose: 750–900 mcg • Treatment course: 14 days (may be repeated after a 1–2 week break)

Research Protocols (Subcutaneous Injection): • Doses range from 250 to 500 mcg per day • Administered once daily, typically in the morning • Cycle duration: 14–30 days, with breaks between cycles

Intranasal Administration (Research): • The nasal route is preferred for CNS effects as it provides more direct access to the brain • Research doses mirror the approved product: 250–500 mcg per administration, 2–3 times daily

Important Notes: • Anxiolytic effects typically become noticeable within the first week and build over 2–4 weeks • Selank does not produce immediate sedation or acute anxiolysis like benzodiazepines • The effects may persist for some time after discontinuation • No abrupt withdrawal effects have been reported

For injectable research, Selank is supplied as lyophilised powder and reconstituted with bacteriostatic water.

Selank has demonstrated an excellent safety profile in clinical studies and post-market use in Russia.

Clinical Trial Safety: In the clinical trials supporting its Russian approval, Selank showed a very favourable safety profile with no serious adverse events attributed to the drug.

Reported Side Effects: • Nasal irritation (with intranasal administration) • Mild headache (occasional) • Metallic taste (transient, with nasal spray) • No significant side effects reported with subcutaneous administration

Key Safety Advantages: • No sedation: Unlike benzodiazepines and many other anxiolytics, Selank does not cause drowsiness or impair alertness • No cognitive impairment: Actually improves cognitive function rather than impairing it • No dependence or addiction: No evidence of physical or psychological dependence • No withdrawal syndrome: Discontinuation does not produce rebound anxiety or other withdrawal symptoms • No tolerance: Efficacy does not appear to diminish with continued use within standard treatment courses • Immune support rather than suppression: Unlike many anxiolytics that can suppress immune function, Selank actually enhances it

Considerations: • Long-term safety data beyond the standard Russian treatment courses is limited • Safety in pregnancy and breastfeeding has not been established • Interactions with other CNS-active medications have not been comprehensively studied • Individuals with autoimmune conditions should exercise caution due to Selank's immune-stimulating properties

Selank is not approved by Health Canada. Its regulatory approval is limited to Russia, where it is available as a prescription nasal spray (Selank®).

In Canada, Selank's regulatory status is as a research chemical: • Available through research chemical suppliers for legitimate research purposes • Not available through Canadian pharmacies or compounding pharmacies • Not a controlled substance in Canada • Not listed on WADA's Prohibited List

The Russian approval of Selank is not recognised by Health Canada. The clinical data supporting its approval in Russia was generated under different regulatory standards than those required by Health Canada or the FDA, and the trials have not been replicated in Western clinical settings.

For Canadians interested in Selank: • Research-grade Selank from chemical suppliers does not carry the same quality assurances as the Russian pharmaceutical product • Nasal spray formulations from research suppliers may differ in concentration and delivery characteristics from the approved Selank® product • Third-party COAs and purity testing are essential when sourcing Selank • Canadian researchers should be aware that much of the published literature is in Russian-language journals

Selank represents an interesting case study in global regulatory divergence — a compound with regulatory approval in one country that remains entirely unregulated elsewhere. This disparity reflects differences in regulatory standards, clinical trial requirements, and pharmaceutical market dynamics between Russia and Western nations.